- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05552976
En studie for å evaluere CC-92480 i kombinasjon med karfilzomib og deksametason (480Kd) versus karfilzomib og deksametason (Kd) hos deltakere med residiverende eller refraktært myelomatose (SUCCESSOR-2)
En fase 3, to-trinns, randomisert, multisenter, åpen studie som sammenligner CC-92480 (BMS-986348), Carfilzomib og Dexamethason (480Kd) versus Carfilzomib og Dexamethason (Kd) hos deltakere med residiverende RR eller Refractory )
The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM: SUCCESSOR-2.
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Fase 3
Kontakter og plasseringer
Studiesteder
-
-
-
Buenos Aires, Argentina, 1431
- Local Institution - 0150
-
Córdoba, Argentina, 5000
- Local Institution - 0151
-
-
Buenos Aires
-
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, C1426ANZ
- Local Institution - 0008
-
-
Buenos Aires F.D.
-
ABB, Buenos Aires F.D., Argentina, C1199ABB
- Local Institution - 0079
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, Argentina, 2000
- Local Institution - 0182
-
-
Tucumán Province
-
San Miguel de Tucumán, Tucumán Province, Argentina, 4000
- Local Institution - 0319
-
-
-
-
New South Wales
-
Camperdown, New South Wales, Australia, 2050
- Local Institution - 0077
-
Gosford, New South Wales, Australia, 2250
- Local Institution - 0160
-
Port Macquarie, New South Wales, Australia, 2444
- Local Institution - 0263
-
St Leonards, New South Wales, Australia, 2065
- Local Institution - 0078
-
Sydney, New South Wales, Australia, 2010
- Local Institution - 0026
-
-
South Australia
-
Adelaide, South Australia, Australia, 5000
- Local Institution - 0024
-
-
Victoria
-
Bendigo, Victoria, Australia, 3550
- Local Institution - 0131
-
East Melbourne, Victoria, Australia, 3002
- Local Institution - 0224
-
Heidelberg, Victoria, Australia, 3084
- Local Institution - 0127
-
Melbourne, Victoria, Australia, 3065
- Local Institution - 0025
-
-
-
-
-
Rio de Janeiro, Brasil, 20775-001
- Local Institution - 0075
-
São Paulo, Brasil, 04537-080
- Local Institution - 0073
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brasil, 41253-190
- Local Institution - 0121
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brasil, 90470-340
- Local Institution - 0076
-
-
São Paulo
-
São Paulo, São Paulo, Brasil, 01509-010
- Local Institution - 0085
-
-
-
-
-
Plovdiv, Bulgaria, 4002
- Local Institution - 0305
-
Sofia, Bulgaria, 1407
- Local Institution - 0309
-
Sofia, Bulgaria, 1431
- Local Institution - 0304
-
-
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 2Y9
- Local Institution - 0183
-
-
Ontario
-
London, Ontario, Canada, N6A 5W9
- Local Institution - 0275
-
Toronto, Ontario, Canada, M5G 2M9
- Local Institution - 0184
-
-
-
-
-
Cali, Colombia, 760035
- Local Institution - 0155
-
-
Antioquia
-
Medellín, Antioquia, Colombia, 05034
- Local Institution - 0153
-
-
Cesar Department
-
Valledupar, Cesar Department, Colombia, 200001
- Local Institution - 0156
-
-
Cundinamarca
-
Bogota, Cundinamarca, Colombia, 111151
- Local Institution - 0154
-
-
Santander Department
-
Piedecuesta, Santander Department, Colombia, 681017
- Local Institution - 0324
-
-
-
-
-
Vejle, Danmark, 7100
- Local Institution - 0125
-
-
Central Jutland
-
Aarhus, Central Jutland, Danmark, 8200
- Local Institution - 0032
-
-
Region Sjælland
-
Roskilde, Region Sjælland, Danmark, 4000
- Local Institution - 0065
-
-
Region Syddanmark
-
Odense, Region Syddanmark, Danmark, 5000
- Local Institution - 0129
-
-
-
-
Alabama
-
Mobile, Alabama, Forente stater, 36604
- Local Institution - 0046
-
-
California
-
Cerritos, California, Forente stater, 90703
- Local Institution - 0005
-
Irvine, California, Forente stater, 92618
- Local Institution - 0190
-
Los Angeles, California, Forente stater, 90017
- Local Institution - 0187
-
Santa Rosa, California, Forente stater, 95403
- Local Institution - 0344
-
Stockton, California, Forente stater, 95204
- Local Institution - 0339
-
-
Florida
-
Fort Myers, Florida, Forente stater, 33901
- Local Institution - 0341
-
St. Petersburg, Florida, Forente stater, 33705
- Local Institution - 0342
-
West Palm Beach, Florida, Forente stater, 33401
- Local Institution - 0340
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30303
- Local Institution - 0348
-
Atlanta, Georgia, Forente stater, 30322
- Local Institution - 0291
-
-
Idaho
-
Boise, Idaho, Forente stater, 83706
- Saint Alphonsus Regional Medical Center
-
-
Maryland
-
Annapolis, Maryland, Forente stater, 21401
- Local Institution - 0289
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02215
- Local Institution - 0204
-
-
Minnesota
-
Minneapolis, Minnesota, Forente stater, 55404
- Local Institution - 0346
-
-
New Jersey
-
Little Silver, New Jersey, Forente stater, 07739
- Local Institution - 0222
-
-
New York
-
The Bronx, New York, Forente stater, 10467
- Local Institution - 0199
-
-
Ohio
-
Cleveland, Ohio, Forente stater, 44106
- Local Institution - 0322
-
Columbus, Ohio, Forente stater, 43214
- Local Institution - 0172
-
-
Rhode Island
-
Providence, Rhode Island, Forente stater, 02903
- Local Institution - 0321
-
-
South Carolina
-
Greer, South Carolina, Forente stater, 29650
- Local Institution - 0338
-
-
Tennessee
-
Chattanooga, Tennessee, Forente stater, 37404
- Local Institution - 0349
-
Nashville, Tennessee, Forente stater, 37203
- Local Institution - 0323
-
-
Texas
-
Fort Worth, Texas, Forente stater, 76104
- Local Institution - 0337
-
Houston, Texas, Forente stater, 77025
- Local Institution - 0328
-
Houston, Texas, Forente stater, 77030
- Local Institution - 0044
-
Temple, Texas, Forente stater, 76508
- Local Institution - 0195
-
-
Virginia
-
Norfolk, Virginia, Forente stater, 23502
- Local Institution - 0345
-
Roanoke, Virginia, Forente stater, 24014
- Local Institution - 0343
-
-
Washington
-
Tacoma, Washington, Forente stater, 98405
- Local Institution - 0006
-
Vancouver, Washington, Forente stater, 98684
- Local Institution - 0347
-
-
West Virginia
-
Morgantown, West Virginia, Forente stater, 26506
- Local Institution - 0243
-
-
Wisconsin
-
Marshfield, Wisconsin, Forente stater, 54449
- Local Institution - 0336
-
-
-
-
Achaḯa
-
Pátrai, Achaḯa, Hellas, 26504
- Local Institution - 0136
-
-
Attikí
-
Athens, Attikí, Hellas, 11528
- Local Institution - 0135
-
-
Thessaloníki
-
Thessaloniki, Thessaloníki, Hellas, 570 10
- Local Institution - 0134
-
-
-
-
-
Hksar, Hong Kong
- Local Institution - 0178
-
-
-
-
-
Chandigarh, India, 160012
- Local Institution - 0230
-
-
Haryana
-
Gurgaon, Haryana, India, 122001
- Local Institution - 0167
-
-
Karnataka
-
Bengaluru, Karnataka, India, 560027
- Local Institution - 0161
-
-
Maharashtra
-
Mumbai, Maharashtra, India, 400012
- Local Institution - 0168
-
Thane, Maharashtra, India, 400602
- Local Institution - 0171
-
-
National Capital Territory of Delhi
-
New Delhi, National Capital Territory of Delhi, India, 110085
- Local Institution - 0170
-
-
Punjab
-
Mohali, Punjab, India, 160055
- Local Institution - 0261
-
-
Tamil Nadu
-
Chennai, Tamil Nadu, India, 600036
- Local Institution - 0174
-
-
Telangana
-
Hyderabad, Telangana, India, 500033
- Local Institution - 0165
-
Hyderabad, Telangana, India, 500068
- Local Institution - 0310
-
Hyderabad, Telangana, India, 500084
- Local Institution - 0164
-
-
-
-
-
Jerusalem, Israel, 9112001
- Local Institution - 0277
-
-
Central District
-
Holon, Central District, Israel, 5810001
- Local Institution - 0264
-
Tsrifin, Central District, Israel, 70300
- Local Institution - 0267
-
-
-
-
-
Bologna, Italia, 40138
- Local Institution - 0189
-
Catanzaro, Italia, 88100
- Local Institution - 0148
-
Lecce, Italia, 73100
- Local Institution - 0147
-
Pisa, Italia, 56100
- Local Institution - 0144
-
Udine, Italia, 33100
- Local Institution - 0146
-
-
Emilia-Romagna
-
Meldola, Emilia-Romagna, Italia, 47014
- Local Institution - 0145
-
-
Lombardy
-
Milan, Lombardy, Italia, 20122
- Local Institution - 0143
-
-
Milano
-
Rozzano, Milano, Italia, 20089
- Local Institution - 0142
-
-
-
-
-
Chiba, Japan, 260-8677
- Local Institution - 0215
-
Fukuoka, Japan, 810-8563
- Local Institution - 0226
-
Fukuoka, Japan, 815-8555
- Local Institution - 0235
-
Kumamoto, Japan, 860-8556
- Local Institution - 0220
-
Kyoto, Japan, 602-8566
- Local Institution - 0216
-
Nagasaki, Japan, 852-8104
- Local Institution - 0213
-
Okayama, Japan, 701-1192
- Local Institution - 0212
-
Osaka, Japan, 545-8586
- Local Institution - 0301
-
Tokyo, Japan, 105-8461
- Local Institution - 0241
-
Tokyo, Japan, 150-8935
- Local Institution - 0218
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japan, 467-8602
- Local Institution - 0269
-
-
Chiba
-
Kashiwa, Chiba, Japan, 277-8577
- Local Institution - 0214
-
-
Fukuoka
-
Kitakyushu-shi, Fukuoka, Japan, 806-8501
- Local Institution - 0210
-
-
Hokkaido
-
Sapporo, Hokkaido, Japan, 003-0804
- Local Institution - 0211
-
-
Ibaraki
-
Higashiibaraki, Ibaraki, Japan, 3113117
- Local Institution - 0217
-
-
Ishikawa-ken
-
Kanazawa, Ishikawa-ken, Japan, 920-8641
- Local Institution - 0300
-
-
Iwate
-
Shiwa-gun Yahaba-cho, Iwate, Japan, 028-3695
- Local Institution - 0209
-
-
Kanagawa
-
Kamakura, Kanagawa, Japan, 247-8533
- Local Institution - 0234
-
-
Saitama
-
Koshigaya, Saitama, Japan, 343-0845
- Local Institution - 0225
-
-
Tokyo
-
Koto-ku, Tokyo, Japan, 135-8550
- Local Institution - 0219
-
tabashi City, Tokyo, Japan, 173-8610
- Local Institution - 0236
-
-
Yamanashi
-
Chūō, Yamanashi, Japan, 409-3898
- Local Institution - 0303
-
-
-
-
-
Taiyuan, Kina, 030032
- Local Institution - 0059
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kina, 100020
- Local Institution - 0061
-
Beijing, Beijing Municipality, Kina, 100043
- Local Institution - 0057
-
Beijing, Beijing Municipality, Kina, 100730
- Local Institution - 0056
-
-
Fujian
-
Fuzhou, Fujian, Kina, 350000
- Local Institution - 0123
-
-
Guangdong
-
Guangzhou, Guangdong, Kina, 510000
- Local Institution - 0138
-
-
Henan
-
Zhengzhou, Henan, Kina, 450008
- Local Institution - 0051
-
-
Hubei
-
Wuhan, Hubei, Kina, 430002
- Local Institution - 0066
-
Wuhan, Hubei, Kina, 430030
- Local Institution - 0054
-
-
Hunan
-
Changsha, Hunan, Kina, 410013
- Local Institution - 0071
-
Changsha, Hunan, Kina, 410013
- Local Institution - 0103
-
-
Jiangsu
-
Nanjing, Jiangsu, Kina, 210009
- Local Institution - 0180
-
Nantong, Jiangsu, Kina, 226001
- Local Institution - 0111
-
Suzhou, Jiangsu, Kina, 215006
- Local Institution - 0104
-
Wuxi, Jiangsu, Kina, 214023
- Local Institution - 0069
-
-
Jiangxi
-
Nanchang, Jiangxi, Kina, 330006
- Local Institution - 0095
-
-
Jilin
-
Changchun, Jilin, Kina, 130021
- Local Institution - 0052
-
-
Liaoning
-
Shenyang, Liaoning, Kina, 110001
- Local Institution - 0096
-
Shenyang, Liaoning, Kina, 110004
- Local Institution - 0176
-
-
Shaanxi
-
Xi'an, Shaanxi, Kina, 710126
- Local Institution - 0060
-
-
Shandong
-
Jinan, Shandong, Kina, 250012
- Local Institution - 0072
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Kina, 200025
- Local Institution - 0118
-
Shanghai, Shanghai Municipality, Kina, 200080
- Local Institution - 0317
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Kina, 300060
- Local Institution - 0091
-
-
Yunnan
-
Kunming, Yunnan, Kina, 650101
- Local Institution - 0058
-
-
Zhejiang
-
Hangzhou, Zhejiang, Kina, 310003
- Local Institution - 0050
-
Wenzhou, Zhejiang, Kina, 32500
- Local Institution - 0115
-
-
-
-
-
Enschede, Nederland, 7512 KZ
- Local Institution - 0194
-
-
North Brabant
-
Breda, North Brabant, Nederland, 4818 CK
- Local Institution - 0113
-
-
-
-
-
Oslo, Norge, 0450
- Local Institution - 0081
-
-
Hordaland
-
Bergen, Hordaland, Norge, 5021
- Local Institution - 0049
-
-
Rogaland
-
Stavanger, Rogaland, Norge, 4021
- Local Institution - 0112
-
-
-
-
-
San Juan, Puerto Rico, 00909
- Local Institution - 0316
-
-
-
-
-
Brasov, Romania, 500052
- Local Institution - 0284
-
Bucharest, Romania, 022328
- Local Institution - 0302
-
Bucharest, Romania, 030171
- Local Institution - 0287
-
Sibiu, Romania, 557260
- Local Institution - 0306
-
-
Bucharest
-
Bucharest, Bucharest, Romania, 022328
- Local Institution - 0282
-
-
-
-
Central Singapore
-
Singapore, Central Singapore, Singapore, 119074
- Local Institution - 0158
-
Singapore, Central Singapore, Singapore, 169608
- Local Institution - 0159
-
-
-
-
-
Granada, Spania, 18012
- Local Institution - 0107
-
Madrid, Spania, 28015
- Local Institution - 0047
-
Málaga, Spania, 29010
- Local Institution - 0105
-
-
Barcelona [Barcelona]
-
Badalona, Barcelona [Barcelona], Spania, 08916
- Local Institution - 0126
-
Barcelona, Barcelona [Barcelona], Spania, 08035
- Local Institution - 0092
-
L'Hospitalet Del Llobregat, Barcelona [Barcelona], Spania, 08908
- Local Institution - 0038
-
-
Madrid, Comunidad de
-
Madrid, Madrid, Comunidad de, Spania, 28009
- Local Institution - 0200
-
Majadahonda, Madrid, Comunidad de, Spania, 28222
- Local Institution - 0108
-
-
Santa Cruz De Tenerife
-
San Cristóbal de La Laguna, Santa Cruz De Tenerife, Spania, 38320
- Local Institution - 0201
-
-
Valenciana, Comunitat
-
Valencia, Valenciana, Comunitat, Spania, 46010
- Local Institution - 0037
-
-
-
-
-
Birmingham, Storbritannia, B9 5SS
- Local Institution - 0273
-
Leeds, Storbritannia, LS9 7TF
- Local Institution - 0080
-
Taunton, Storbritannia, TA1 5DA
- Local Institution - 0040
-
-
Devon
-
Plymouth, Devon, Storbritannia, Pl6 8DH
- Local Institution - 0139
-
-
England
-
Cringleford, England, Storbritannia, NR4 7UY
- Local Institution - 0067
-
-
Glasgow City
-
Glasgow, Glasgow City, Storbritannia, G12 0YN
- Local Institution - 0196
-
-
-
-
Seoul-teukbyeolsi [Seoul]
-
Seoul, Seoul-teukbyeolsi [Seoul], Sør -Korea, 03080
- Local Institution - 0238
-
Seoul, Seoul-teukbyeolsi [Seoul], Sør -Korea, 06351
- Local Institution - 0239
-
Seoul, Seoul-teukbyeolsi [Seoul], Sør -Korea, 06591
- Local Institution - 0240
-
-
-
-
-
Kaohsiung City, Taiwan, 82445
- Local Institution - 0012
-
Taichung, Taiwan, 407
- Local Institution - 0001
-
Tainan, Taiwan, 704
- Local Institution - 0002
-
Taipei, Taiwan, 11217
- Local Institution - 0162
-
-
Chiayi
-
Chiayi City, Chiayi, Taiwan, 613
- Local Institution - 0274
-
-
Kaohsiung
-
Kaohsiung Niao Sung Dist, Kaohsiung, Taiwan, 83301
- Local Institution - 0177
-
-
-
-
-
Berlin, Tyskland, 12203
- Local Institution - 0007
-
Cologne, Tyskland, 50937
- Local Institution - 0102
-
Dresden, Tyskland, 01307
- Local Institution - 0329
-
Düsseldorf, Tyskland, 40479
- Local Institution - 0334
-
Heidelberg, Tyskland, D-69120
- Local Institution - 0015
-
Leipzig, Tyskland, 04103
- Local Institution - 0030
-
Nuremberg, Tyskland, 90419
- Local Institution - 0133
-
Würzburg, Tyskland, 97080
- Local Institution - 0014
-
-
Baden-Wurttemberg
-
Ulm, Baden-Wurttemberg, Tyskland, 89081
- Local Institution - 0124
-
-
Bavaria
-
Munich, Bavaria, Tyskland, 81241
- Local Institution - 0330
-
-
Lower Saxony
-
Hanover, Lower Saxony, Tyskland, 30161
- Local Institution - 0333
-
-
North Rhine-Westphalia
-
Dortmund, North Rhine-Westphalia, Tyskland, 44263
- Local Institution - 0335
-
-
Schleswig-Holstein
-
Kiel, Schleswig-Holstein, Tyskland, 24105
- Local Institution - 0029
-
-
Thuringia
-
Jena, Thuringia, Tyskland, 07747
- Local Institution - 0331
-
-
-
-
-
Budapest, Ungarn, 1088
- Local Institution - 0042
-
Budapest, Ungarn, 1097
- Local Institution - 0019
-
-
Baranya
-
Pécs, Baranya, Ungarn, 7624
- Local Institution - 0036
-
-
Hajdú-Bihar
-
Debrecen, Hajdú-Bihar, Ungarn, 4032
- Local Institution - 0043
-
-
Szabolcs-Szatmár-Bereg
-
Nyíregyháza, Szabolcs-Szatmár-Bereg, Ungarn, 4400
- Local Institution - 0094
-
-
-
-
-
Linz, Østerrike, 4020
- Local Institution - 0020
-
Vienna, Østerrike, 1090
- Local Institution - 0017
-
-
State of Vienna
-
Vienna, State of Vienna, Østerrike, 1060
- Local Institution - 0266
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria
- Participant has documented diagnosis of multiple myeloma and measurable disease, defined as any of the following:.
i) Myeloma-protein (M-protein) ≥ 0.5 grams/deciliter (g/dL) by serum protein electrophoresis (sPEP), or.
ii) M-protein ≥ 200 milligrams (mg)/24-hour urine collection by urine protein electrophoresis (uPEP) or,.
iii) For participants without measurable disease in sPEP or uPEP: serum free light chain levels > 100 mg/liter (L) (10 mg/dL) involved light chain and an abnormal κ/λ free light chain ratio.
- Participant has received at least one prior line of anti-myeloma therapy. Note: One line can contain several phases (e.g., induction, [with or without] hematopoietic stem cell transplant, (with or without) consolidation, and/or [with or without] maintenance therapy).
- Participant must have received prior treatment with lenalidomide and at least 2 cycles of an anti-CD38 monoclonal antibody (mAb) (participants who were intolerant of an anti-CD38 mAb and received < 2 cycles are still eligible).
- Participant achieved minimal response or better to at least 1 prior anti-myeloma therapy.
- Participant must have documented disease progression during or after their last antimyeloma regimen.
Exclusion Criteria
- Participant who has had prior treatment with mezigdomide or carfilzomib.
- Participant has previously received allogeneic stem cell transplant at any time or received autologous stem cell transplant within 12 weeks of initiating study treatment.
- Other protocol-defined Inclusion/Exclusion criteria apply.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: Kd (karfilzomib + deksametason)
|
Specified dose on specified days
Andre navn:
Specified dose on specified days
Andre navn:
|
|
Eksperimentell: MeziKd (Mezigdomide + Carfilzomib + Deksametason)
|
Specified dose on specified days
Andre navn:
Specified dose on specified days
Andre navn:
Specified dose on specified days
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Progresjonsfri overlevelse (PFS)
Tidsramme: Opptil ca 5 år
|
Opptil ca 5 år
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Progresjonsfri overlevelse 2 (PFS-2)
Tidsramme: Opptil ca 5 år
|
Opptil ca 5 år
|
|
|
Total overlevelse (OS)
Tidsramme: Opptil ca 5 år
|
Opptil ca 5 år
|
|
|
Tid til respons (TTR)
Tidsramme: Opptil ca 5 år
|
Opptil ca 5 år
|
|
|
Varighet av respons (DOR)
Tidsramme: Opptil ca 5 år
|
Opptil ca 5 år
|
|
|
Tid til progresjon (TTP)
Tidsramme: Opptil ca 5 år
|
Opptil ca 5 år
|
|
|
Tid til neste behandling (TTNT)
Tidsramme: Opptil ca 5 år
|
Opptil ca 5 år
|
|
|
Minimal Residual Disease (MRD) negativitetsrate
Tidsramme: Opptil ca 5 år
|
Opptil ca 5 år
|
|
|
Antall deltakere med uønskede hendelser (AE)
Tidsramme: Opptil ca 5 år
|
Opptil ca 5 år
|
|
|
Samlet respons (OR)
Tidsramme: Opptil ca 5 år
|
Opptil ca 5 år
|
|
|
Recommended Mezigdomide Dose
Tidsramme: Up to 12 months
|
Stage 1 only |
Up to 12 months
|
|
Plasma concentrations of Mezigdomide in Combination with Carfilzomib and Dexamethasone
Tidsramme: Up to 176 days
|
Stage 1 only |
Up to 176 days
|
|
Rate Of Very Good Partial Response (VGPR) Or Better (VGPRR)
Tidsramme: Up to approximately 5 years
|
VGPRR will be calculated as the percentage of participants who achieve best response of VGPR or better according to the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma. |
Up to approximately 5 years
|
|
Complete Response (CR) Or Better (CRR)
Tidsramme: Up to approximately 5 years
|
CRR will be calculated as the percentage of participants who achieve best response of CR or better according to the IMWG Uniform Response Criteria for Multiple Myeloma. |
Up to approximately 5 years
|
|
Change From Baseline in the European Organization for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30)
Tidsramme: Up to approximately 5 years
|
The EORTC QLQ-C30 is the most commonly used quality of life instrument in oncology trials. The QLQ-C30 consists of 30 questions incorporated into 5 functional domains physical, role, cognitive, emotional, and social), 9 symptom/other scales (fatigue, pain, nausea and vomiting, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties), and a single global Quality of Life (QoL)/global health status score. Items in the functional and symptom scale use raw participant response of 1 to 4, where 1 = "not at all" and 4 = "very much." The 2 global items contain responses ranging from 1 "very poor" to 7 "excellent." The recall period is 1 week. All domain scores are transformed in a range from 0 to 100, where a higher functional score indicates more favorable outcomes and a higher score on the symptom domains indicates a less favorable participant outcome. Stage 2 only. |
Up to approximately 5 years
|
|
Change From Baseline in the European Quality of Life Multiple Myeloma Module (EORTC QLQ-MY20)
Tidsramme: Up to approximately 5 years
|
The EORTC QLQ-MY20 is a 20-item myeloma module intended for use among participants varying in disease stage and treatment modality. Participants rate symptoms or problems on a scale from 1 to 4 where 1 = "not at all" and 4 = "very much." Stage 2 only. |
Up to approximately 5 years
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Bristol-Myers Squibb, Bristol-Myers Squibb
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Vaskulære sykdommer
- Kardiovaskulære sykdommer
- Patologiske prosesser
- Neoplasmer
- Sykdomsattributter
- Sykdommer i immunsystemet
- Neoplasmer etter histologisk type
- Hematologiske sykdommer
- Lymfoproliferative lidelser
- Immunproliferative lidelser
- Neoplasmer, plasmacelle
- Hemostatiske lidelser
- Paraproteinemier
- Blodproteinforstyrrelser
- Hemoragiske lidelser
- Patologiske tilstander, tegn og symptomer
- Hemic og lymfatiske sykdommer
- Tilbakefall
- Multippelt myelom
- Svovelforbindelser
- Organiske kjemikalier
- Hydrokarboner
- Hydrokarboner, syklisk
- Hydrokarboner, aromatisk
- Polysykliske forbindelser
- Gravadienes
- Gravaner
- Steroider
- Smeltede ringforbindelser
- Steroider, fluorert
- Benzenderivater
- Sulfonsyrer
- Svovelsyrer
- Gravadienetrioler
- Benzenesulfonater
- Arylsulfonater
- Arylsulfonsyrer
- Deksametason
- Kalsiumdobesilat
- carfilzomib
Andre studie-ID-numre
- CA057-008
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
IPD-delingstidsramme
See Plan Description
Tilgangskriterier for IPD-deling
See Plan Description
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
- CSR
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .